|
1
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar
|
|
3
|
de Bono JS, Tolcher AW and Rowinsky EK:
The future of cytotoxic therapy: selective cytotoxicity based on
biology is the key. Breast Cancer Res. 5:154–159. 2003.PubMed/NCBI
|
|
4
|
Zafonte BT, Hulit J, Amanatullah DF,
Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP and
Pestell RG: Cell-cycle dysregulation in breast cancer: breast
cancer therapies targeting the cell cycle. Front Biosci.
5:D938–D961. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Munagala R, Aqil F and Gupta RC: Promising
molecular targeted therapies in breast cancer. Indian J Pharmacol.
43:236–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schwartz GK and Shah MA: Targeting the
cell cycle: a new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chin YW, Balunas MJ, Chai HB and Kinghorn
AD: Drug discovery from natural sources. AAPS J. 8:E239–E253.
2006.PubMed/NCBI
|
|
9
|
Rizk AM, Hammouda FM, El-Missiry MM,
Radwan HM and Evans FJ: Biologically active diterpene esters from
euphorbia peplus. Phytochemistry. 24:1605–1606. 1985. View Article : Google Scholar
|
|
10
|
Rasool N, Khan AQ and Malik A: A
taraxerane type triterpene from Euphorbia tirucalli.
Phytochemistry. 28:1193–1195. 1989. View Article : Google Scholar
|
|
11
|
de Melo JG, Santos AG, de Amorim EL, do
Nascimento SC and de Albuquerque UP: Medicinal plants used as
antitumor agents in Brazil: an ethnobotanical approach. Evid Based
Complement Alternat Med. 2011:3653592011.PubMed/NCBI
|
|
12
|
Akihisa T, Ogihara J, Kato J, Yasukawa K,
Ukiya M, Yamanouchi S and Oishi K: Inhibitory effects of
triterpenoids and sterols on human immunodeficiency virus-1 reverse
transcriptase. Lipids. 36:507–512. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Akihisa T, Kithsiri Wijeratne EM, Tokuda
H, Enjo F, Toriumi M, Kimura Y, Koike K, Nikaido T, Tezuka Y and
Nishino H: Eupha-7,9(11),24-trien-3beta-ol (‘antiquol C’) and other
triterpenes from Euphorbia antiquorum latex and their inhibitory
effects on Epstein-Barr virus activation. J Nat Prod. 65:158–162.
2002.PubMed/NCBI
|
|
14
|
Dutra RC, Claudino RF, Bento AF, Marcon R,
Schmidt EC, Bouzon ZL, Pianowski LF and Calixto JB: Preventive and
therapeutic euphol treatment attenuates experimental colitis in
mice. PLoS One. 6:e271222011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dutra RC, de Souza PR, Bento AF, Marcon R,
Bicca MA, Pianowski LF and Calixto JB: Euphol prevents experimental
autoimmune encephalomyelitis in mice: evidence for the underlying
mechanisms. Biochem Pharmacol. 83:531–542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Passos GF, Medeiros R, Marcon R,
Nascimento AF, Calixto JB and Pianowski LF: The role of PKC/ERK1/2
signaling in the anti-inflammatory effect of tetracyclic triterpene
euphol on TPA-induced skin inflammation in mice. Eur J Pharmacol.
698:413–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yasukawa K, Akihisa T, Yoshida ZY and
Takido M: Inhibitory effect of euphol, a triterpene alcohol from
the roots of Euphorbia kansui, on tumour promotion by
12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in
mouse skin. J Pharm Pharmacol. 52:119–124. 2000. View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
19
|
O’Connor PM, Jackman J, Bae I, Myers TG,
Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN,
et al: Characterization of the p53 tumor suppressor pathway in cell
lines of the National Cancer Institute anticancer drug screen and
correlations with the growth-inhibitory potency of 123 anticancer
agents. Cancer Res. 57:4285–4300. 1997.
|
|
20
|
Gillett C, Fantl V, Smith R, Fisher C,
Bartek J, Dickson C, Barnes D and Peters G: Amplification and
overexpression of cyclin D1 in breast cancer detected by
immunohistochemical staining. Cancer Res. 54:1812–1817.
1994.PubMed/NCBI
|
|
21
|
Zukerberg LR, Yang WI, Gadd M, Thor AD,
Koerner FC, Schmidt EV and Arnold A: Cyclin D1 (PRAD1) protein
expression in breast cancer: approximately one-third of
infiltrating mammary carcinomas show overexpression of the cyclin
D1 oncogene. Mod Pathol. 8:560–567. 1995.
|
|
22
|
Lin SY, Xia W, Wang JC, Kwong KY, Spohn B,
Wen Y, Pestell RG and Hung MC: Beta-catenin, a novel prognostic
marker for breast cancer: its roles in cyclin D1 expression and
cancer progression. Proc Natl Acad Sci USA. 97:4262–4266. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: a review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pagano M, Tam SW, Theodoras AM,
Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M:
Role of the ubiquitin-proteasome pathway in regulating abundance of
the cyclin-dependent kinase inhibitor p27. Science. 269:682–685.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nigro JM, Baker SJ, Preisinger AC, Jessup
JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee
P, et al: Mutations in the p53 gene occur in diverse human tumour
types. Nature. 342:705–708. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Girard F, Strausfeld U, Fernandez A and
Lamb NJ: Cyclin A is required for the onset of DNA replication in
mammalian fibroblasts. Cell. 67:1169–1179. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Resnitzky D, Hengst L and Reed SI: Cyclin
A-associated kinase activity is rate limiting for entrance into S
phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol.
15:4347–4352. 1995.PubMed/NCBI
|
|
28
|
Knoblich JA and Lehner CF: Synergistic
action of Drosophila cyclins A and B during the G2-M transition.
EMBO J. 12:65–74. 1993.PubMed/NCBI
|
|
29
|
Li H, Sun L, Tang Z, Fu L, Xu Y, Li Z, Luo
W, Qiu X and Wang E: Overexpression of TRIM24 correlates with tumor
progression in non-small cell lung cancer. PLoS One. 7:e376572012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Darzynkiewicz Z, Bruno S, Del Bino G,
Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of
apoptotic cells measured by flow cytometry. Cytometry. 13:795–808.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nieves-Neira W and Pommier Y: Apoptotic
response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the
8 human breast cancer cell lines of the NCI Anticancer Drug Screen:
multifactorial relationships with topoisomerase I, protein kinase
C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer.
82:396–404. 1999. View Article : Google Scholar
|
